To clarify the apparently opposing effects of Piezo2 channels and check their clinical relevance in breast cancer, we retrospectively chose a consecutive cohort of breast cancer patients undergoing surgery with a clinical follow-up of 5 years. The gene discussed is PIEZO2; the disease is breast carcinoma.